Villers-lès-Nancy, France, 22 September 2014 - 18:30 (CET)

PRESS RELEASE Operating profit up 11.4% in first-half 2014

€ millions

H1 2014

H1 2013

Change

Sales (1 January to 30 June)

58.31

59.14

(1.4%)

Operating profit

13.32

11.96

+ 11.4%

Net profit/(loss)

8.68

8.10

+ 7.3%

Net income - Group share

8.72

8.05

+ 8.3%

Basic earnings per share (in €)

2.87

2.65

+ 8.3%

The Board of Directors of PHARMAGEST INTERACTIVE examined and approved the accounts for H1 2014 during its meeting on 12 September 2014, chaired by Thierry Chapusot. The statutory auditors performed an interim review of the half-year consolidated financial statements.

Profit up in the first half

As expected, the Pharmaceutical Companies business declined sharply in first-half
2014, with the fall particularly marked in Communication Services, which saw 31.5% or
€2.9 million eroded from sales in the period. Nonetheless, all other PHARMAGEST
Group businesses delivered a strong performance and sales gained 4% in H1 2014 compared with H1 2013, when restated for Communication Services.
Growth in our high-margin business largely offset the decline in the low-margin
Communication Services and operating profit was up 11.4% to €13.32 million.
Net profit/(loss) came in at €8.68 million (growth of 7.3%), while net income - Group share climbed 8.3% year-on-year.
As at 30 June 2014, basic earnings per share amounted to €2.87 (up from €2.65 at 30
June 2013).

Consolidated balance sheet - key data

The Group's cash position remained stable, with excellent available liquidity of €47.2 million at 30 June 2014 (before payment of dividends), up from €40.4 million at the end of first-half 2013 (after payment of dividends).
Equity capital was €77 million at 30 June 2014.

PHARMAGEST INTERACTIVE

2014 interim results Press Release, 22 September 2014

Selected financial information for first-half 2014

- In May 2014, PHARMAGEST INTERACTIVE increased its holding in DIATELIC (its subsidiary specialising in artificial intelligence and expert systems to predict the evolution of patients' health) to 86.9%.
- During the same period and after a lengthy investment phase lasting more than one year, the Group's e-Health business commenced marketing of its first electronic
devices.

Outlook for the second half of 2014

- Organic growth will continue in PHARMAGEST Group's long-established activities through the launch of new offerings and innovative products, in terms of both technology and customer support, all aimed at maintaining excellent profitability.
- As previously stated, Communication Services will continue to fall back.
- The E-Health Division is set to reap the first fruits of the Group's investments in this area. It will pursue its deployment strategy and maintain a strong presence in the national and regional e-health initiatives being trialled in France.
- The PHARMAGEST Group will continue to keep a close eye out for acquisition opportunities in innovative technologies related to the health sphere.

Financial calendar:

- Interim results presentation meeting on 23 September 2014, Paris
- MidCap Event on 2 and 3 October 2014, Paris
- Publication of Q3 turnover on 13 November 2014

About the PHARMAGEST Group:

The PHARMAGEST Group is the French leader in computer systems for pharmacies, with a 43.5% share of the market, 9,800 clients and more than 750 employees. Since September 2007, the PHARMAGEST Group has also been present in Northern Europe with a 12% market share in Belgium and Luxembourg through its subsidiary SABCO.

As a preferred partner to pharmacists for almost 30 years now, the PHARMAGEST Group designs innovative computer solutions for pharmacies and is developing a high-potential E-Business E-Media activity intended for laboratories.

The PHARMAGEST Group is also developing innovative new solutions for Retirement Homes (Care Comes and day centres for the elderly) through its subsidiary MALTA INFORMATIQUE.

The first Logiciel de Gestion à Portail Intégré (Integrated Portal Management Software - LGPI Global Services®), creator of value for the patient, pharmacist and laboratory, dynamises sales, optimises purchases and enriches advice to the patient. It is also the first permanent- impact medium for pharmacies, supplying laboratories with direct communication towards the pharmacist and his or her patients.

Au cœur de la révolution numérique qui s'installe peu à peu dans le quotidien des professionnels de santé comme des patients, le Groupe PHARMAGEST a créé début 2012 une activité e-Santé, regroupant les filiales DIATELIC (systèmes experts prédictifs), DOMEDIC EUROPE (pilulier intelligent DO-Pill SecuR™) et KAPELSE (dispositifs électroniques de santé), activité structurellement soutenue par l'obtention de plusieurs agréments en tant qu'Hébergeur de Données de Santé.

Listed on the Euronext Paris™ - Compartment B

Indices CAC® SMALL90 and CAC® All-Tradable by inclusion

ISIN: FR 0000077687 - Reuters : PHA.PA - Bloomberg: - PMGI FP

Pharmagest shares are eligible for the Equity Savings Plan

Find all the latest news on the PHARMAGEST Group at www.pharmagest.com

Chairman of the Board:

Thierry CHAPUSOT

PHARMAGEST INTERACTIVE

2014 interim results Press Release, 22 September 2014

Chief Executive Officer:

Dominique PAUTRAT

Tel. 03 83 15 90 67 - dominique.pautrat@pharmagest.com

Analyst and Investor Relations:

Administrative and Financial Director: Jean-Yves Samson

Tel. 03 83 15 90 67 - jean-yves.samson@pharmagest.com

Press Relations:

FIN'EXTENSO - Isabelle Aprile

Tel. 01 39 97 61 22 - mailto:i.aprile@finextenso.fri.aprile@finextenso.fr

distributed by